Understand · Discuss · Plan together

BRCA1 and BRCA2 Explained

Everyone has BRCA1 and BRCA2 genes. It is a harmful change in a gene—not simply “having the gene”—that can increase risk.

Chapter 4 of 16

4 of 16
Explore all 16 chapters

What these genes do

BRCA proteins help repair damaged DNA. A pathogenic or likely pathogenic germline variant can increase susceptibility to breast, ovarian, fallopian tube and primary peritoneal cancers. Male breast, prostate and pancreatic cancer risks can also be relevant; the pattern and size of risk differ between BRCA1 and BRCA2.

Reading a risk number

There is no single percentage that applies to every carrier. Ask: which cancer, by what age, in which population, and before or after preventive care? Published estimates often come from international studies and are not a personal forecast for an Indian family. A carrier may never develop cancer.

What a confirmed result may change

  • Earlier breast surveillance and discussion of risk-reducing options.
  • A gynaecological discussion about fallopian tube and ovarian risk after family completion.
  • For men, breast awareness and a prostate-screening discussion, particularly with BRCA2.
  • Testing of adult blood relatives for the exact familial variant.
  • Treatment options for selected cancer diagnoses; eligibility still depends on the cancer and clinical setting.

Avoid common misunderstandings

HER2-positive breast cancer is not the same as a BRCA result. A tumour BRCA finding needs assessment for a possible germline origin. A BRCA VUS is not a confirmed cancer-predisposing finding. A negative limited consumer test cannot exclude all harmful BRCA changes.

Your next conversation

Bring the complete report and ask whether the result is confirmed germline, what screening is due now and whether decisions about fertility should precede preventive surgery. See chapter 13 for age-specific surveillance examples and chapter 14 for surgical trade-offs.

Sources and further reading

Accessible sources checked: 19 October 2026. International recommendations are identified where used; care in India requires individual clinical assessment. No claim is made to have directly verified restricted NCCN guidance.